• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Constantine S. Mitsiades, MD, PhD


  • Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, Nardone A, Song Y, Bradner J, Mitsiades N, Mitsiades CS, Osborne CK, Schiff R, O'Malley BW.An epigenomic approach to therapy for tamoxifen-resistant breast cancer.Cell Res. 2014 May 30.
  • Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, Buhrlage SJ, Liang J, Liu J, Yang G, Brown JR, Treon SP, Mitsiades CS, Griffin JD, Liu Q, Gray NS.Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.ACS Chem Biol. 2014 May 16(5):1086-91.
  • Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC.A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.Blood. 2014 Mar 6;123(10):1461-9.
  • Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC.Future agents and treatment directions in multiple myeloma.Expert Rev Hematol. 2014 Feb;7(1):127-41.
  • Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG.The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.Science. 2014 Jan 17;343(6168):305-9.
  • de Haart SJ, van de Donk NW, Minnema MC, Huang JH, Aarts-Riemens T, Bovenschen N, Yuan H, Groen RW, McMillin DW, Jakubikova J, Lokhorst HM, Martens AC, Mitsiades CS, Mutis T.Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.Clin Cancer Res. 2013 Oct 15;19(20):5591-601.
  • O'Connor R, Ooi MG, Meiller J, Jakubikova J, Klippel S, Delmore J, Richardson P, Anderson K, Clynes M, Mitsiades CS, O'Gorman P.The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.Cancer Chemother Pharmacol. 2013 Apr 16.
  • Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA, Moreau P, Siegel DS, Jagannath S, Anderson KC.Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.Leuk Res. 2013 Apr 9.
  • McMillin DW, Negri JM, Mitsiades CS.The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.Nat Rev Drug Discov. 2013 Mar;12(3):217-28. Review.
  • Weisberg E, Liu Q, Zhang X, Nelson E, Sattler M, Liu F, Nicolais M, Zhang J, Mitsiades C, Smith RW, Stone R, Galinsky I, Nonami A, Griffin JD, Gray N.Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.PLoS ONE. 2013;8(2):e56473.
  • Rosovsky R, Hong F, Tocco D, Connell B, Mitsiades C, Schlossman R, Ghobrial I, Lockridge L, Warren D, Bradwin G, Doyle M, Munshi N, Soiffer RJ, Anderson KC, Weller E, Richardson P.Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.British Journal of Haematology. 2013 Feb;160(3):351-8.
  • Bae J, Munshi A, Li C, Samur M, Prabhala R, Mitsiades C, Anderson KC, Munshi NC.Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.J Immunol. 2013 Feb 1;190(3):1360-71.
  • McMillin DW, Mitsiades CS.High-throughput approaches to discover novel immunomodulatory agents for cancer.Oncoimmunology. 2012 Nov 1;1(8):1406-1408.
  • Reagan MR, Seib FP, McMillin DW, Sage EK, Mitsiades CS, Janes SM, Ghobrial IM, Kaplan DL.Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ.J Breast Cancer. 2012 Sep;15(3):273-82.
  • Klippel S, Jakubikova J, Delmore J, Ooi M, McMillin D, Kastritis E, Laubach J, Richardson PG, Anderson KC, Mitsiades CS.Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.British Journal of Haematology. 2012 Nov;159(3):340-51.
  • van de Donk NW, Görgün G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, Laubach J, Nijhof IS, Raymakers RA, Lokhorst HM, Richardson PG, Anderson KC.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Cancer Management and Research. 2012;4:253-68.
  • Kawahara M, Pandolfi A, Bartholdy B, Barreyro L, Will B, Roth M, Okoye-Okafor UC, Todorova TI, Figueroa ME, Melnick A, Mitsiades CS, Steidl U.H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia.Cancer Cell. 2012 Aug 14;22(2):194-208.
  • Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez HF, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U.Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.Blood. 2012 Aug 9;120(6):1290-8.
  • Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC.Canonical and non canonical Hedgehog pathway in the pathogenesis of multiple myeloma.Blood. 2012 Jul 20.
  • Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.Blood. 2012 Jul 12;120(2):386-94.
  • Rickles RJ, Tam WF, Giordano TP, Pierce LT, Farwell M, McMillin DW, Necheva A, Crowe D, Chen M, Avery W, Kansra V, Nawrocki ST, Carew JS, Giles FJ, Mitsiades CS, Borisy AA, Anderson KC, Lee MS.Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening.Mol Cancer Ther. 2012 Jul;11(7):1432-42.
  • McMillin DW, Delmore J, Negri JM, Vanneman M, Schlossman RL, Munshi NC, Laubach J, Richardson PG, Dranoff G, Anderson KC, Mitsiades CS.Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of anti-tumor immune function.Blood. 2012 Jan 30.
  • Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS.BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc.Cell. 2011 Sep 16;146(6):904-17.
  • McMillin DW, Delmore J, Negri J, Ooi M, Klippel S, Miduturu CV, Gray NS, Richardson PG, Anderson KC, Kung AL, Mitsiades CS.Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.PLoS ONE. 2011;6(7):e20226.
  • Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, Richardson PG.Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.J Clin Oncol. 2011 May 10;29(14):1916-23. Review.
  • Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG.Tanespimycin as antitumor therapy.Clin Lymphoma Myeloma Leuk. 2011 Feb 1;11(1):17-22.
  • Lonial S, Mitsiades CS, Richardson PG.Treatment options for relapsed and refractory multiple myeloma.Clin Cancer Res. 2011 Mar 15;17(6):1264-77.
  • Rajpal R, Dowling P, Meiller J, Clarke C, Murphy WG, O'Connor R, Kell M, Mitsiades C, Richardson P, Anderson KC, Clynes M, O'Gorman P.A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients.Proteomics. 2011 Feb 14.
  • Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG.Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.Expert Rev Hematol. 2011 Feb;4(1):51-60.
  • Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS.Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.Blood. 2011 Feb 14.
  • Mitsiades CS.How "immunomodulatory" are IMIDs?.Blood. 2011 Feb 3;117(5):1440-1.
  • Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC.Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.British Journal of Haematology. 2011 Feb;152(4):367-79. Review.
  • McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, Jakubikova J, Ooi M, Hayden P, Schlossman R, Munshi NC, Lengauer C, Richardson PG, Anderson KC, Mitsiades CS.Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.British Journal of Haematology. 2011 Feb;152(4):420-32.
  • Richardson PG, Chanan-Khan AA, Alsina M, Albitar M, Berman D, Messina M, Mitsiades CS, Anderson KC.Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.British Journal of Haematology. 2010 Aug;150(4):438-45.
  • Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Blood. 2010 Aug 5;116(5):679-86.
  • Mateos MV, Cibeira MT, Richardson PG, Prosper F, Oriol A, de la Rubia J, Lahuerta JJ, García-Sanz R, Extremera S, Szyldergemajn S, Corrado C, Singer H, Mitsiades CS, Anderson KC, Bladé J, San Miguel J.Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.Clin Cancer Res. 2010 Jun 15;16(12):3260-9.
  • Hideshima T, Mitsiades C, Ikeda H, Chauhan D, Raje N, Gorgun G, Hideshima H, Munshi NC, Richardson PG, Carrasco DR, Anderson KC.A proto-oncogene Bcl-6 is upregulated in the bone marrow microenvironment in multiple myeloma cells.Blood. 2010 May 6;115(18):3772-5.
  • McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC, Mitsiades CS.Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.Nat Med. 2010 Apr;16(4):483-9.
  • Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K.Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S4-S12.
  • Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM.Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):252-7.
  • Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG.The use of novel agents in the treatment of relapsed and refractory multiple myeloma.Leukemia..
  • Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N.Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.Clin Cancer Res. 2009 Dec 1;15(23):7153-60.
  • Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC.Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.J Clin Oncol. 2009 Dec 1;27(34):5713-9.
  • Mitsiades CS, Anderson KC.Epigenetic modulation in hematologic malignancies: challenges and progress.J Natl Compr Canc Netw. 2009 Nov;7 Suppl 8:S1-12; quiz S14-6. Review.
  • Negri JM, McMillin DW, Delmore J, Mitsiades N, Hayden P, Klippel S, Hideshima T, Chauhan D, Munshi NC, Buser CA, Pollard J, Richardson PG, Anderson KC, Mitsiades CS.In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.British Journal of Haematology. 2009 Dec;147(5):672-6.
  • Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.Novel therapies in the treatment of multiple myeloma.J Natl Compr Canc Netw. 2009 Oct;7(9):947-60. Review.
  • Blotta S, Tassone P, Prabhala RH, Tagliaferri P, Cervi D, Amin S, Jakubikova J, Tai YT, Podar K, Mitsiades CS, Zullo A, Franco B, Anderson KC, Munshi NC.Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.Blood. 2009 Oct 8;114(15):3276-84.
  • Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.Novel therapies in the treatment of multiple myeloma.J Natl Compr Canc Netw..
  • Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, Bianchi G, Podar K, Tai YT, Mitsiades C, Raje N, Jaye DL, Kumar SK, Richardson P, Munshi N, Anderson KC.Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.Cancer Cell. 2009 Oct 6;16(4):309-23.
  • Iliaki E, Poulaki V, Mitsiades N, Mitsiades CS, Miller JW, Gragoudas ES.Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy.Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4898-904.
  • Poulaki V,Mitsiades CS,Kotoula V,Negri J,McMullan C,Miller JW,Marks PA,Mitsiades N.Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4072-9.
  • Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Podar K, Hideshima T, Bianchi G, Mitsiades C, Raje N, Tai Y-T, Jaye DL, Kumar SK, Schlossman R, Richardson P, Munshi N, Anderson KC.Functional Interaction of plasmacytoid dendritic cells with multiple myeloma cells: a novel therapeutic target.Cancer Cell..
  • Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA.Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.J Clin Oncol. 2009 Jul 20;27(21):3518-25.
  • McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.Cancer Res. 2009 Jul 15;69(14):5835-42.
  • Laubach JP,Mitsiades CS,Roccaro AM,Ghobrial IM,Anderson KC,Richardson PG.Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenstroms Macroglobulinemia.Leuk Lymphoma. 2009 May;50(5):694-702. Review.
  • Mitsiades CS,Hideshima T,Chauhan D,McMillin DW,Klippel S,Laubach JP,Munshi NC,Anderson KC,Richardson PG.Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.Semin Hematol. 2009 Apr;46(2):166-75. Review.
  • Mitsiades CS,Rouleau C,Echart C,Menon K,Teicher B,Distaso M,Palumbo A,Boccadoro M,Anderson KC,Iacobelli M,Richardson PG.Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.Clin Cancer Res. 2009 Feb 15;15(4):1210-21.
  • Kotoula V,Sozopoulos E,Litsiou H,Fanourakis G,Koletsa T,Voutsinas G,Tseleni-Balafouta S,Mitsiades CS,Wellmann A,Mitsiades N.Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.Endocr Relat Cancer. 2009 Jun;16(2):565-572.
  • Birmann BM, Tamimi RM, Giovannucci E, Rosner B, Hunter DJ, Kraft P, Mitsiades C, Anderson KC, Colditz GA.Insulin-like Growth Factor-1- and Interleukin-6-related Gene Variation and Risk of Multiple Myeloma.Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):282-8.
  • Mitsiades CS,Ocio EM,Pandiella A,Maiso P,Gajate C,Garayoa M,Vilanova D,Montero JC,Mitsiades N,McMullan CJ,Munshi NC,Hideshima T,Chauhan D,Aviles P,Otero G,Faircloth G,Mateos MV,Richardson PG,Mollinedo F,San-Miguel JF,Anderson KC.Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.Cancer Res. 2008 Jul 1;68(13):5216-25.
  • Munshi NC,Mitsiades C,Richardson PG,Anderson KC.Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma.Nat Clin Pract Oncol. 2008 Jul;5(7):374-5.
  • Weisberg E, Wright RD, McMillin DW, Mitsiades C, Ray A, Barrett R, Adamia S, Stone R, Galinsky I, Kung AL, Griffin JD.Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.Mol Cancer Ther. 2008 May;7(5):1121-9.
  • Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D.Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.Leuk Lymphoma. 2008 Mar;49(3):502-7.
  • Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG.From the bench to the bedside: emerging new treatments in multiple myeloma.Best Pract Res Clin Haematol. 2007 Dec;20(4):797-816. Review.
  • Kastritis E, Mitsiades CS, Dimopoulos MA, Richardson PG.Management of relapsed and relapsed refractory myeloma.Hematol Oncol Clin North Am. 2007 Dec;21(6):1175-215, x. Review.
  • Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, Munshi NC, Anderson KC.The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.Hematol Oncol Clin North Am. 2007 Dec;21(6):1007-34, vii-viii. Review.
  • Hayden PJ, Mitsiades CS, Anderson KC, Richardson PG.Novel therapies in myeloma.Curr Opin Hematol. 2007 Nov;14(6):609-15. Review.
  • Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N.The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4706-19.
  • Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP.Increased natural killer cell expression of CD16, and augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIA-158 V/V and V/F polymorphism.Blood. 2007 Oct 1;110(7):2561-4.
  • Mitsiades CS, Hayden P, Kotoula V, McMillin DW, McMullan C, Negri J, Delmore JE, Poulaki V, Mitsiades N.Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.J Clin Endocrinol Metab. 2007 Dec;92(12):4845-52.
  • Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC.Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.British Journal of Haematology. 2007 Sep;138(6):783-91.
  • Ghobrial J, Ghobrial IM, Mitsiades C, Leleu X, Hatjiharissi E, Moreau AS, Roccaro A, Schlossman R, Hideshima T, Anderson KC, Richardson P.Novel therapeutic avenues in myeloma: changing the treatment paradigm.Oncology (Huntingt). 2007 Jun;21(7):785-92; discussion 798-800. Review.
  • Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC.Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.Nat Rev Cancer. 2007 Aug;7(8):585-98. Review.
  • Weisberg E, Kung AL, Wright RD, Moreno D, Catley L, Ray A, Zawel L, Tran M, Cools J, Gilliland G, Mitsiades C, McMillin DW, Jiang J, Hall-Meyers E, Griffin JD.Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.Mol Cancer Ther. 2007 Jul;6(7):1951-61.
  • Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K.New drugs for myeloma.Oncologist. 2007 Jun;12(6):664-89. Review.
  • Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li CQ, Trudel LJ, Yasui H, Vallet S, Kutok JL, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GN, Keefer LK, Shami PJ, Anderson KC.JS-K, a GST-activated nitric oxide generator, induces DNA double strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.Blood. 2007 Jul 15;110(2):709-18.
  • Munshi NC, Mitsiades CS, Richardson PG, Anderson KC.Does maintenance therapy with thalidomide benefit patients with multiple myeloma?.Nat Clin Pract Oncol. 2007 Jul;4(7):394-5.
  • Bae J, Mitsiades C, Tai YT, Bertheau R, Shammas M, Batchu RB, Li C, Catley L, Prabhala R, Anderson KC, Munshi NC.Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell.J Immunol. 2007 Jun 15;178(12):7730-7.
  • Mitsiades CS, Mitsiades NS, Richardson PG, Munshi NC, Anderson KC.Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.J Cell Biochem. 2007 Jul 1;101(4):950-68. Review.
  • Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, Carrasco DE, Zheng M, He H, Tai YT, Mitsiades C, Anderson KC, Carrasco DR.Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.Proc Natl Acad Sci U S A. 2007 May 1;104(18):7516-21.
  • Richardson PG, Hideshima T, Mitsiades C, Anderson KC.The emerging role of novel therapies for the treatment of relapsed myeloma.J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. Review.
  • Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F, Giagounidis AA, Klement G, Steidl U, Otu HH, Czibere A, Prall WC, Iking-Konert C, Shayne M, Ramoni MF, Gattermann N, Haas R, Mitsiades CS, Fung ET, Libermann TA.Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1307-12.
  • Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC.Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.Blood. 2007 Apr 15;109(8):3177-88.
  • Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC.A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.Blood. 2006 Nov 15;108(10):3458-64.
  • Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC.The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions.Eur J Cancer. 2006 Jul;42(11):1564-73. Review.
  • Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC.Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.Br J Haematol. 2006 Jul;134(2):145-56.
  • Mitsiades CS, Richardson PG, Anderson KC.The theraputic use of vitamin K compounds in multiple myeloma.Haematologica. 2006 May;91(5):578b.
  • Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KC.Anti-myeloma activity of heat shock protein-90 inhibition.Blood. 2006 Feb 1;107(3):1092-100.
  • Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC.Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.Blood. 2006 May 15;107(10):4053-62.
  • Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC.A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.Cancer Cell. 2005 Nov;8(5):407-19.
  • Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC.Focus on multiple myeloma.Cancer Cell. 2004 Nov;6(5):439-44.
  • Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, Garca-Echeverra C, Pearson MA, Hofmann F, Anderson KC, Kung AL.Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.Cancer Cell. 2004 Mar;5(3):221-30.
  • Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC.Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5.
  • Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, Maxwell CA, Pilarski L, Hideshima T, Hoffman RM, Anderson KC.Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.Cancer Res. 2003 Oct 15;63(20):6689-96.
  • Mitsiades CS, Mitsiades N, Richardson PG, Treon SP, Anderson KC.Novel biologically based therapies for Waldenstrom's macroglobulinemia.Semin Oncol. 2003 Apr;30(2):309-12.
  • Mitsiades CS, Mitsiades N, Treon SP, Anderson KC.Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias.Semin Oncol. 2003 Apr;30(2):156-60.
  • Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC.Molecular sequelae of histone deacetylase inhibition in human malignant B cells.Blood. 2003 May 15;101(10):4055-62.
  • Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC.The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.Blood. 2003 Mar 15;101(6):2377-80.
  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC.Molecular sequelae of proteasome inhibition in human multiple myeloma cells.Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9.
  • Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC.Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.Oncogene. 2002 Aug 22;21(37):5673-83.
  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC.Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.Blood. 2002 Jun 1;99(11):4079-86.
  • Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP.Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.Blood. 2002 Mar 15;99(6):2162-71.
  • Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC.TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.Blood. 2001 Aug 1;98(3):795-804.